Fred Saad, CQ, MD, FRCS, FCAHS

Fred Saad, MD, discusses the importance of timing when incorporating radium-223 into prostate cancer treatment.

[The baseline patient population] represents what we see in the real world, with a median age of 73. [This] is older than what we see in [many] clinical trials.

Fred Saad, MD, discusses the rationale behind the long-term safety analysis for radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer with bone-predominant disease.

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy and safety data from the PEACE study of radium-223 and enzalutamide in mCRPC.

Fred Saad, MD, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Fred Saad, MD, professor and chief of Urology, director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses results of a trial that investigated early use of radium-223 dichloride (Xofigo) in patients with asymptomatic metastatic castration-resistant prostate cancer.

Fred Saad, MD, University of Montreal Hospital Centers, discusses the safety and efficacy of the apalutamide combination for patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis that examined which patients with metastatic castration-resistant prostate cancer are able to receive the recommended 6-doses of radium-223 dichloride (Xofigo).

Fred Saad, MD, FRCSC, principal scientist, full professor, Department of Surgery, chair in Prostate Cancer Research, Université de Montréal, medical director, Interdisciplinary Urologic Oncology Group, head, Urologic Oncology, CHUM, discusses the expanded access program (EAP) of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses the use of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).